PHARMACEUTICAL
Dry Eye
Recent Scientific Publications on Dry Eye
COMET CLINICAL TRIALS
AR-15512 Registration Clinical Studies
POSTER
A Review of Phase 3 Trial Results for Acoltremon (AR-15512) Ophthalmic Solution 0.003%
VIDEO
AR-15512: Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist
DRY EYE CLINICAL TRIAL
A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)
WHITE PAPER
Evolution of Systane® Artificial Tears
WHITE PAPER
Thermal Pulsation Systems and Topical Immunomodulators for Managing Meibomian Gland Dysfunction
TRYPTYR® (acoltremon ophthalmic solution) 0.003% is a prescription eye drop used for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Use TRYPTYR® exactly as your healthcare provider tells you to.
TRYPTYR® is for use in the eye. Each single-dose vial of TRYPTYR will give you enough medicine to treat both of your eyes. TRYPTYR® vial is for 1-time use only. Use right away after opening and do not reuse.
Keep the unopened single-dose vials in the original foil package until ready to use.
Wash your hands before each use. Do not let the tip of the single-dose vial touch your eye or any other surface to avoid eye injury or infection.
If you use TRYPTYR® with other eye medicines, wait at least 5 minutes between using TRYPTYR® and the other medicines.
If you wear contact lenses, remove them before using TRYPTYR®. Wait 15 minutes after dosing before putting contact lenses back in your eyes.
Call your healthcare provider right away if you get an allergic reaction or other eye problems such as eye injury, eye infection, or eye pain.
The most common side effect of TRYPTYR® in clinical trials was burning or stinging sensation in the eye upon instillation, which was reported in 50% of patients.
EYSUVIS® is the first and only FDA-approved corticosteroid for short-term dry eye treatment.
IMPORTANT SAFETY INFORMATION
EYSUVIS® should not be used if you have a viral infection in your eye. Talk to your doctor before using EYSUVIS® if you think you may have a viral, bacterial, or fungal eye infection.
Your doctor should examine your eyes before prescribing EYSUVIS®, to check for increased eye pressure or damage to the surface of the eye.
Consult your doctor if pain, redness, itching, or inflammation develops or gets worse. Wash your hands well before each use.
Do not allow the dropper tip to touch any surface, as this may contaminate the suspension. Shake the bottle for two to three seconds before using. If a dose is missed, take the missed dose when remembered.
Remove contact lenses before using EYSUVIS®; they may be reinserted 15 minutes later. The most common adverse drug reaction following the use of EYSUVIS® for two weeks was instillation site pain, which was reported in 5% of patients.